Literature DB >> 25736266

Proteomics of ovarian cancer: functional insights and clinical applications.

Mohamed A Elzek1, Karin D Rodland.   

Abstract

In the past decade, there has been an increasing interest in applying proteomics to assist in understanding the pathogenesis of ovarian cancer, elucidating the mechanism of drug resistance, and in the development of biomarkers for early detection of ovarian cancer. Although ovarian cancer is a spectrum of different diseases, the strategies for diagnosis and treatment with surgery and adjuvant therapy are similar across ovarian cancer types, increasing the general applicability of discoveries made through proteomics research. While proteomic experiments face many difficulties which slow the pace of clinical applications, recent advances in proteomic technology contribute significantly to the identification of aberrant proteins and networks which can serve as targets for biomarker development and individualized therapies. This review provides a summary of the literature on proteomics' contributions to ovarian cancer research and highlights the current issues, future directions, and challenges. We propose that protein-level characterization of primary lesion in ovarian cancer can decipher the mystery of this disease, improve diagnostic tools, and lead to more effective screening programs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25736266      PMCID: PMC4776756          DOI: 10.1007/s10555-014-9547-8

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  142 in total

Review 1.  Proteomics by mass spectrometry: approaches, advances, and applications.

Authors:  John R Yates; Cristian I Ruse; Aleksey Nakorchevsky
Journal:  Annu Rev Biomed Eng       Date:  2009       Impact factor: 9.590

2.  The dynamic range problem in the analysis of the plasma proteome.

Authors:  Glen L Hortin; Denis Sviridov
Journal:  J Proteomics       Date:  2009-07-17       Impact factor: 4.044

Review 3.  Proteomic developments in the analysis of formalin-fixed tissue.

Authors:  Ove J R Gustafsson; Georgia Arentz; Peter Hoffmann
Journal:  Biochim Biophys Acta       Date:  2014-10-12

4.  Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer.

Authors: 
Journal:  Obstet Gynecol       Date:  2011-03       Impact factor: 7.661

5.  Comparative proteomics of ovarian epithelial tumors.

Authors:  Hee Jung An; Dong Su Kim; Yong Kyu Park; Sei Kwang Kim; Yoon Pyo Choi; Suki Kang; Boxiao Ding; Nam Hoon Cho
Journal:  J Proteome Res       Date:  2006-05       Impact factor: 4.466

6.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

7.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

8.  LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker.

Authors:  Yifeng He; Xin Wu; Xiaohui Liu; Guoquan Yan; Congjian Xu
Journal:  J Proteome Res       Date:  2010-10-28       Impact factor: 4.466

9.  HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

Authors:  T Van Gorp; I Cadron; E Despierre; A Daemen; K Leunen; F Amant; D Timmerman; B De Moor; I Vergote
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

10.  Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

Authors:  Yuan Yuan; Eliezer M Van Allen; Larsson Omberg; Nikhil Wagle; Ali Amin-Mansour; Artem Sokolov; Lauren A Byers; Yanxun Xu; Kenneth R Hess; Lixia Diao; Leng Han; Xuelin Huang; Michael S Lawrence; John N Weinstein; Josh M Stuart; Gordon B Mills; Levi A Garraway; Adam A Margolin; Gad Getz; Han Liang
Journal:  Nat Biotechnol       Date:  2014-06-22       Impact factor: 54.908

View more
  21 in total

1.  Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.

Authors:  Gunjal Garg; Ali Yilmaz; Praveen Kumar; Onur Turkoglu; David G Mutch; Matthew A Powell; Barry Rosen; Ray O Bahado-Singh; Stewart F Graham
Journal:  Metabolomics       Date:  2018-11-24       Impact factor: 4.290

Review 2.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

3.  A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer.

Authors:  Kalpana Deepa Priya Dorayappan; Miranda L Gardner; Colin L Hisey; Roman A Zingarelli; Brentley Q Smith; Michelle D S Lightfoot; Rajan Gogna; Meghan M Flannery; John Hays; Derek J Hansford; Michael A Freitas; Lianbo Yu; David E Cohn; Karuppaiyah Selvendiran
Journal:  Cancer Res       Date:  2019-05-16       Impact factor: 12.701

4.  Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations.

Authors:  Mitchell Acland; Noor A Lokman; Clifford Young; Dovile Anderson; Mark Condina; Chris Desire; Tannith M Noye; Wanqi Wang; Carmela Ricciardelli; Darren J Creek; Martin K Oehler; Peter Hoffmann; Manuela Klingler-Hoffmann
Journal:  Cancers (Basel)       Date:  2022-06-02       Impact factor: 6.575

5.  Mapping human N-linked glycoproteins and glycosylation sites using mass spectrometry.

Authors:  Liuyi Dang; Li Jia; Yuan Zhi; Pengfei Li; Ting Zhao; Bojing Zhu; Rongxia Lan; Yingwei Hu; Hui Zhang; Shisheng Sun
Journal:  Trends Analyt Chem       Date:  2019-02-13       Impact factor: 12.296

Review 6.  Nanomaterials for cancer therapy: current progress and perspectives.

Authors:  Zhe Cheng; Maoyu Li; Raja Dey; Yongheng Chen
Journal:  J Hematol Oncol       Date:  2021-05-31       Impact factor: 17.388

7.  Hsa_circ_0001756 promotes ovarian cancer progression through regulating IGF2BP2-mediated RAB5A expression and the EGFR/MAPK signaling pathway.

Authors:  Jing Ji; Chen Li; Jinfeng Wang; Lei Wang; Huifang Huang; Ying Li; Jing Fang
Journal:  Cell Cycle       Date:  2022-02-03       Impact factor: 5.173

8.  Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research.

Authors:  Christopher S Hughes; Melissa K McConechy; Dawn R Cochrane; Tayyebeh Nazeran; Anthony N Karnezis; David G Huntsman; Gregg B Morin
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

9.  MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.

Authors:  Agata Swiatly; Agnieszka Horala; Joanna Hajduk; Jan Matysiak; Ewa Nowak-Markwitz; Zenon J Kokot
Journal:  BMC Cancer       Date:  2017-07-06       Impact factor: 4.430

10.  Highly-accurate metabolomic detection of early-stage ovarian cancer.

Authors:  David A Gaul; Roman Mezencev; Tran Q Long; Christina M Jones; Benedict B Benigno; Alexander Gray; Facundo M Fernández; John F McDonald
Journal:  Sci Rep       Date:  2015-11-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.